Work

Papillon-Lefèvre syndrome with excellent response to risankizumab

Year: 2026

Type: article

Abstract: Papillon-Lefèvre syndrome (PLS) is a rare autosomal recessive genodermatosis. It is clinically characterized by diffuse palmoplantar keratoderma (PPK), psoriasiform skin lesions, and rapidly progressive periodontopathy. Management of PLS can be challenging. Herein, we present the case of a 27-year-old female who experienced poor response to multiple therapies, including topical keratolytic creams, oral isotretinoin and acitretin, and the tumor necrosis factor (TNF) inhibitor adalimumab. Notably, she achieved complete resolution of her cutaneous manifestations following treatment with the interleukin (IL)-23 inhibitor risankizumab.

Source: Dermatology Reports

DOI: 10.4081/dr.2026.10309

Authors: Latifah Alibrahim, Sarah Alrashid, Majed Aleissa

Institution: King Abdulaziz Medical City

Language: English

Topic: Genetic and rare skin diseases.

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $539